Feed AMRX
AM

Amneal Pharmaceuticals

AMRX · NASDAQ

$18.08 +8.59% (+$1.43)
1M -0.60%
Market Cap $5.77B
P/E Ratio 36.69x
Div. Yield -
ROE -

Bulios Fair Price

$13.99

22.6% downside

Current Price

$18.08

Undervalued Fair Value Overvalued

According to Bulios Fair Price, AMRX is currently overvalued relative to its market price. How does it work?

Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?

Piotroski F-Score Strong
7/9
Valuation
28 /100
Expensive
P/B 174.83x
P/S 1.85x
P/E 36.69x
Growth
70 /100
Growing
Rev. growth 10.92%
FCF growth N/A
Book val. growth N/A
Profitability
46 /100
Moderate
FCF margin 2.67%
Op. margin 12.93%
Gross margin 39.32%
Quality
67 /100
Excellent
ROA 4.17%
Asset turnover 0.83x
ROIC 14.32%
Debt
28 /100
High
Net debt/EBITDA 4.08x
Int. coverage 2.01x
Debt/Equity 84.54x
Stability
50 /100
Moderate
Profitable years 1
EPS volatility 73.33%
Beta 1.24x

Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more

Ask StockBot about AMRX
Online

About the company

Amneal Pharmaceuticals, Inc. is an American pharmaceutical company focused on the development, manufacturing, and distribution of generic and specialty medications. The company specializes in a broad range of therapeutic areas, including cardiovascular diseases, neurological disorders, oncology, and more. Amneal also produces its own branded products targeting specific conditions. The company is known for its ability to provide affordable medications while continuing to develop innovative therapies.

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

CEO

Chirag K. Patel

Employees

8,700

Headquarters

Bridgewater

Upcoming events

29 OCT

Earnings

Upcoming earnings report

42d

We use essential cookies to run the website and optional analytics cookies to measure usage. See our Privacy Policy.